Esen-Danaci Ayşen, Sarandöl Asli, Taneli Fatma, Yurtsever Fatma, Ozlen Nesrin
Celal Bayar University Medical School, Department of Psychiatry, Turkey.
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1434-8. doi: 10.1016/j.pnpbp.2008.03.015. Epub 2008 Apr 1.
Weight gain is a major side effect of antipsychotic treatment. Some atypical antipsychotic agents have profound effects on weight. Body weight is regulated by a complex system, including both peripheral and central factors. Two of the hormones that seem to play an important role in the regulation of food intake, energy metabolism, and body weight are leptin and ghrelin. Leptin is a mediator of long-term regulation of energy balance, suppressing food intake and thereby inducing weight loss. Ghrelin on the other hand is a fast-acting hormone, seemingly playing a role in meal initiation. In this present study it is aimed to compare the effects of five different atypical antipsychotic medications on leptin and ghrelin.
112 patients who were treated either with clozapine (n=20), olanzapine (n=28), risperidone (n=22), quetiapine (n=20) or amisulpride (n=22) as monotherapy for at least one year and age, gender, and body mass index (BMI) matched control group (n=23) were assessed cross-sectionally. Ghrelin and leptin levels were measured with enzyme-immunoassay.
When fasting serum leptin levels were compared between groups, control group had the highest mean value (9.2+/-6.7) and amisulpride group had the lowest mean value (3.7+/-2.1) but still there was no statistically significant difference between six groups (F=1993, p=0.084). In the comparison of the mean values of fasting serum ghrelin levels there was a statistically significant difference between groups (F=11,473, p=0.00). In post-hoc analysis it was seen that the control group had the lowest ghrelin level (194.5+/-86.8). Quetiapine treated group (378.1+/-260.4) had similar fasting serum ghrelin levels to control group. All the other antipsychotic treatment groups had significantly higher levels of fasting serum ghrelin compared to control group, highest in amisulpride treated group (597.0+/-150.0).
The weight-gain side effect of atypical antipsychotics can be related with the orexigenic effect of elevated serum ghrelin rather than leptin deficit. Among the five widely used atypical antipsychotics quetiapine is the only one which does not elevate the ghrelin level.
体重增加是抗精神病药物治疗的主要副作用。一些非典型抗精神病药物对体重有深远影响。体重由一个复杂的系统调节,包括外周和中枢因素。瘦素和胃饥饿素这两种激素似乎在食物摄入、能量代谢和体重调节中起重要作用。瘦素是能量平衡长期调节的介质,抑制食物摄入从而导致体重减轻。另一方面,胃饥饿素是一种速效激素,似乎在进餐开始时起作用。本研究旨在比较五种不同非典型抗精神病药物对瘦素和胃饥饿素的影响。
对112例接受氯氮平(n = 20)、奥氮平(n = 28)、利培酮(n = 22)、喹硫平(n = 20)或氨磺必利(n = 22)单一疗法治疗至少一年的患者以及年龄、性别和体重指数(BMI)匹配的对照组(n = 23)进行横断面评估。用酶免疫测定法测量胃饥饿素和瘦素水平。
比较各组空腹血清瘦素水平时,对照组均值最高(9.2±6.7),氨磺必利组均值最低(3.7±2.1),但六组之间仍无统计学显著差异(F = 1.993,p = 0.084)。比较空腹血清胃饥饿素水平均值时,各组之间有统计学显著差异(F = 11.473,p = 0.00)。事后分析发现对照组胃饥饿素水平最低(194.5±86.8)。喹硫平治疗组(378.1±260.4)空腹血清胃饥饿素水平与对照组相似。所有其他抗精神病治疗组空腹血清胃饥饿素水平均显著高于对照组,氨磺必利治疗组最高(597.0±150.0)。
非典型抗精神病药物的体重增加副作用可能与血清胃饥饿素升高的促食欲作用有关,而非瘦素缺乏。在五种广泛使用的非典型抗精神病药物中,喹硫平是唯一不升高胃饥饿素水平的药物。